Clinical use of Bevacizumab in treating refractory glaucoma

Abstract

UNLABELLED Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab found its way into ophthalmology and clinical practice all around the world. The objective of this review is to present… (More)

1 Figure or Table

Topics

  • Presentations referencing similar topics